Sign In
Buy MRK
$115.17
+0.270 (+0.235%)
At Close: Jun 16, 2026
Merck's VRNA Buyout to Add Novel COPD Therapy: How to Play the Stock?
09:20am, Friday, 11'th Jul 2025
MRK's $10B buyout of VRNA brings in Ohtuvayre, a unique COPD therapy set to bolster its cardio-pulmonary portfolio.
Merck's Verona Acquisition: Plugging A $4B Hole In A $20B Gap
07:10am, Friday, 11'th Jul 2025
Merck's recent acquisition announcement sends a strong signal regarding its urgency to tackle the impending Keytruda patent cliff. The pharmaceutical leader has made an agreement to acquire the COPD d
2 Top Stocks Down 16% and 17% This Year to Buy and Hold
05:36am, Friday, 11'th Jul 2025
Most people love a bargain; investors do too. Purchasing shares of companies that can perform well over long periods is already pretty exciting, but it's even more so when they can be scooped up from
FDA Approves BRAVECTO® QUANTUM (Fluralaner for Extended-Release Injectable Suspension) from Merck Animal Health
04:45pm, Thursday, 10'th Jul 2025
RAHWAY, N.J.--(BUSINESS WIRE)--Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced t
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--U.S. FDA Accepts New Drug Application for Merck's DOR/ISL Once-Daily Two-Drug Regimen for Treatment of Adults with Virologically Suppressed HIV-1.
Merck (MRK) Rises Higher Than Market: Key Facts
06:51pm, Wednesday, 09'th Jul 2025
Merck (MRK) closed the most recent trading day at $83.71, moving +2.88% from the previous trading session.
Measuring Options Activity in MRK & XLV: Healthcare Levels to Watch
04:00pm, Wednesday, 09'th Jul 2025
Rick Ducat turns to the healthcare sector on today's options analysis. He starts with the SPDR Health Care ETF (XLV), noting the recent breakdown of a head and shoulders pattern and potential for both
Major deals involving U.S. drugmakers and biotechs over the past decade
01:46pm, Wednesday, 09'th Jul 2025
Merck is acquiring UK-based Verona Pharma for about $10 billion, as part of the U.S. drugmaker's strategy to diversify beyond its blockbuster cancer treatment Keytruda.
Undercovered Dozen: Roku, Merck, Chevron And More
12:59pm, Wednesday, 09'th Jul 2025
The Undercovered Dozen series highlights 12 lesser-covered stocks weekly, providing investment ideas and sparking community discussion on their potential. Roku, Serve Robotics, Merck, Aeva, Chevron, I
Merck to Buy Verona Pharma for Around $10 Billion
12:36pm, Wednesday, 09'th Jul 2025
Merck agreed to buy respiratory drugmaker Verona Pharma for about $10 billion as it tries to make up for huge expected patent losses. Sales could fall by $18 billion over the next five years.
META Stake in Ray-Ban & Oakley Maker, MRK Acquiring VRNA, TMUS Downgrade
10:30am, Wednesday, 09'th Jul 2025
Meta Platforms (META) is moving to eyewear. As Diane King Hall explains, the Mag 7 giant is seeking to build its own A.I.
Merck Faces Multiple Challenges: Will It Steer Through Successfully?
10:25am, Wednesday, 09'th Jul 2025
MRK banks on new launches as Keytruda faces a looming patent cliff and Gardasil weakens amid China's demand slump.
Merck to buy Verona for $10 billion ahead of Keytruda patent expiration
09:23am, Wednesday, 09'th Jul 2025
CNBC's Angelica Peebles reports on themes emerging in the pharma space.
Merck Strikes $10-Billion Deal For Verona, Secures First-In-Class COPD Drug
09:03am, Wednesday, 09'th Jul 2025
Merck & Co. Inc. MRK agreed on Wednesday to acquire Verona Pharma plc VRNA for $107 per American Depository Share (ADS) for a total transaction value of approximately $10 billion. Each ADS represents
Merck Plots $10 Billion Takeover Of COPD Drugmaker Verona Pharma
09:00am, Wednesday, 09'th Jul 2025
Merck said Wednesday it would buy COPD drugmaker Verona Pharma for $10 billion. The news sent Verona stock flying.
